BMO Reaffirms Outperform on CRISPR Therapeutics (CRSP) After Sirius Collaboration

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best biotech stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s collaboration with Sirius on FXI siRNA SRSD107, BMO Capital reaffirmed its Outperform rating and $75 price target on the company’s shares on September 23. The collaboration has resulted in the start of a Phase II trial for the prevention of venous thromboembolism (VTE), which does not include gene editing.

Clinical evidence from studies on atrial fibrillation (AF) and total knee arthroplasty (TKA) indicates that FXI is an appealing target that may upend the $15 billion thromboembolism market, which is currently dominated by medications that target Factor X.

About 40% of individuals with atrial fibrillation are either untreated or only partially treated, according to BMO Capital, which suggests an enormous demand for novel treatments in this area.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology that uses its proprietary gene sequencing platform to develop precise treatments for diseases that require DNA modification.

While we acknowledge the potential of CRSP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRSP and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.